Replies to post #307531 on Innovation Pharmaceuticals Inc (IPIX)

[cybermich]

You said, "What makes you think this is true..?"

Well third party validation for starters..
and the enthusiasm of those "third parties" evidenced by the willingness to publish peer review articles and the willingness to take the lead in applying for the government grant.

Not just coming from Leo. (even though I personally have no problem trusting him, it is obvious some others do not.) - so it should make those folks happy that we have this important third party validation.

[MinnieM]

Sorry it took so long to respond... seem to have overlooked this post.

No trials can be run without drugs manufactured for use in trials. They have a history of manufacturing drugs since they have a history of running trials. It's absolutely true.

The problem they are facing now is that covid came as a surprise to everyone. Prior to covid, the focus was on Brilacidin OM and UC. Manufacturing arrangements were focused on sachets for OM and oral dosing for UC. As can be seen in recent pr's they are in the manufacturing process for Brilacidin dosing via intravenous (IV) for use in a covid trial. Lack of enough IV drug on hand is likely the reason they haven't been in a covid clinical trial yet. And, that isn't surprising since Leo had no way to anticipate a global covid pandemic.

One of the questions in my mind is which trial do we see first? Brilacidin IV for covid or Brilacidin oral for UC?

Good luck to all and stay safe.






Message in reply to: bolded

"It makes perfect sense to have started manufacturing already. What wouldn't make sense is to not start it when they know they'll need it whether they partner up or go it alone with grant funds. No trials without drugs."

Haven't they pre started B for sachets for OM, and one other indication in another form (than sachets) first (sorry, forget which one)?

What makes you think this is true, and shall "pan out"?